HARTE-HANKS INC

Star Equity’s $38.4 million deal for Harte‑Hanks offers a 100 % premium, blending cash and preferred stock to boost revenue, cut costs, and enhance customer‑experience capabilities.

Harte Hanks Inc. reported a 14.2% decline in revenue to $38.6 million in the second quarter of 2025, citing downturns across all business segments.

Harte Hanks Inc. is navigating market challenges and financial difficulties, but sees opportunities in the evolving health sector to leverage its direct marketing expertise and drive growth.

Harte Hanks Inc’s stock remains under scrutiny as the company navigates leadership changes, controversial health policy decisions, and public scrutiny, with its market position and investor confidence hanging in the balance.